- Home
- ARCT vs MLYS Comparison
ARCT vs MLYS Comparison
Compare ARCT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- MLYS
- Stock Information
- Founded
- ARCT 2013
- MLYS 2019
- Country
- ARCT United States
- MLYS United States
- Employees
- ARCT N/A
- MLYS N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- MLYS Health Care
- Exchange
- ARCT Nasdaq
- MLYS Nasdaq
- Market Cap
- ARCT 487.0M
- MLYS 526.1M
- IPO Year
- ARCT N/A
- MLYS 2023
- Fundamental
- Price
- ARCT $15.88
- MLYS $10.21
- Analyst Decision
- ARCT Strong Buy
- MLYS Strong Buy
- Analyst Count
- ARCT 8
- MLYS 2
- Target Price
- ARCT $61.00
- MLYS $30.00
- AVG Volume (30 Days)
- ARCT 405.9K
- MLYS 263.5K
- Earning Date
- ARCT 03-06-2025
- MLYS 03-20-2025
- Dividend Yield
- ARCT N/A
- MLYS N/A
- EPS Growth
- ARCT N/A
- MLYS N/A
- EPS
- ARCT N/A
- MLYS N/A
- Revenue
- ARCT $160,399,000.00
- MLYS N/A
- Revenue This Year
- ARCT $7.33
- MLYS N/A
- Revenue Next Year
- ARCT $4.71
- MLYS N/A
- P/E Ratio
- ARCT N/A
- MLYS N/A
- Revenue Growth
- ARCT N/A
- MLYS N/A
- 52 Week Low
- ARCT $14.30
- MLYS $8.58
- 52 Week High
- ARCT $45.00
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- ARCT 41.74
- MLYS 44.53
- Support Level
- ARCT $16.03
- MLYS $9.57
- Resistance Level
- ARCT $17.95
- MLYS $10.79
- Average True Range (ATR)
- ARCT 1.29
- MLYS 0.64
- MACD
- ARCT -0.07
- MLYS 0.11
- Stochastic Oscillator
- ARCT 10.29
- MLYS 63.98
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.